Plain-English translation of NCT05719441 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of two new antibodies called and , given together with standard HIV medications, can help people who have just been diagnosed with HIV achieve remission—meaning the virus stays suppressed without needing to take medications forever. Right now, people with HIV need to take medications every day for life. This study hopes to find a better way by treating the infection very early with a combination approach.
Current HIV treatment works well, but people must take medications daily for their entire lives. This trial is exploring whether giving specially designed antibodies early in infection, combined with standard treatment, could help the body control HIV on its own and potentially achieve remission without lifelong daily medication.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new antibody treatment plus HIV medications, or standard HIV medications alone (placebo). You will receive infusions of the antibodies (or placebo) at specific study visits while also taking daily HIV medications. Researchers will monitor your viral levels, immune system response, and overall health through regular blood tests and visits to see whether the combination treatment helps control HIV better or longer than treatment alone.
AI-generated summary from trial data · Aug 21, 2026 · Not medical advice
United States